Innovative therapies for sepsis

BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy
S Krishnagopalan, R P Dellinger

Abstract

Sepsis and septic shock continue to be a major cause of morbidity and mortality. Despite numerous advances in the supportive care of patients with sepsis, the overall mortality has changed little in the past 20 years. Many innovative therapies have been attempted in the field of sepsis, primarily aimed at stopping the cycle of cytokine activation which is part of the systemic inflammatory response. Therapies have also targeted other molecular mediators of inflammation and coagulation. Despite encouraging preliminary preclinical results, most of the early trials in sepsis research have failed to offer hope of improving survival with the use of these innovative therapies. Postulated reasons for the failure of clinical trials include the disparity between animal models and clinical reality, the heterogeneous nature of patient populations and sepsis, and the complexity of the inflammatory cascade. On a more hopeful note, three recent trials assessing corticosteroids, anti-tumour necrosis factor strategy and drotrecogin alfa (rhAPC), respectively, have proclaimed positive results. However, only the drotrecogin alfa trial has been peer reviewed and published.

References

Jul 23, 1992·The New England Journal of Medicine·UNKNOWN Intravenous Immunoglobulin Collaborative Study GroupMichel-Pierre Glauser
Jan 1, 1991·Chest·R L DannerJ E Parillo
Oct 4, 1990·The New England Journal of Medicine·S Baskin, N Lasker
Oct 13, 1988·The New England Journal of Medicine·M H LebelG H McCracken
Jan 12, 1984·The New England Journal of Medicine·S L HoffmanA A Loedin
Nov 11, 1982·The New England Journal of Medicine·E J ZieglerA I Braude
Jun 1, 1993·The Journal of Clinical Investigation·A A CreaseyL B Hinshaw
May 1, 1996·Critical Care Medicine·R P Dellinger
Jan 18, 1997·Lancet·R G WestendorpJ P Vandenbrouke
Jul 1, 1997·Critical Care Medicine·F ZeniC Natanson
Apr 29, 1998·Critical Care Medicine·P E BollaertA Larcan
Aug 29, 1998·Intensive Care Medicine·E F Mammen
Jan 28, 1999·The New England Journal of Medicine·J R O'Dell
May 26, 1999·Infectious Disease Clinics of North America·S M Opal, A S Cross
May 26, 1999·Infectious Disease Clinics of North America·M S Rangel-Frausto
May 26, 1999·Infectious Disease Clinics of North America·T van der Poll, S J van Deventer
May 26, 1999·Infectious Disease Clinics of North America·S Symeonides, R A Balk
Jun 3, 1999·Clinical Chemistry and Laboratory Medicine : CCLM·K Werdan
Jul 23, 1999·Intensive Care Medicine·E Abraham
Aug 18, 1999·JAMA : the Journal of the American Medical Association·J P MiraJ F Dhainaut

❮ Previous
Next ❯

Citations

May 11, 2006·Der Anaesthesist·O Moerer, H Burchardi
Aug 13, 2002·Current Opinion in Hematology·Nigel S Key, E Wesley Ely
May 1, 2004·Critical Care Medicine·Marcel LeviTom van der Poll
Feb 10, 2004·AACN Clinical Issues·Jane Cunneen, Martina Cartwright
Mar 15, 2002·Drugs·Katherine A Lyseng-Williamson, Caroline M Perry
May 13, 2004·PharmacoEconomics·James E Frampton, Rachel H Foster
Jul 11, 2003·Vojnosanitetski pregled. Military-medical and pharmaceutical review·Dordije KaradaglićMilica Popović

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood Clotting Disorders

Thrombophilia includes conditions with increased tendency for excessive blood clotting. Blood clotting occurs when the body has insufficient amounts of specialized proteins that make blood clot and stop bleeding. Here is the latest research on blood clotting disorders.